#Oncolytics Biotech #pelareorep #ASCO

Oncolytics Biotech to Present Promising Pelareorep Data at ASCO GI Symposium

Oncolytics Biotech® Inc., a prominent player in the field of immunotherapy based in the U.S. and Canada, is set to unveil significant findings regarding its innovative drug, pelareorep, aimed at some of the most challenging gastrointestinal cancers. This presentation will occur at the much-anticipated 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium slated for January 23-25 in San Francisco.

Breakthrough Innovations in Cancer Treatment

The abstracts accepted for this symposium highlight groundbreaking research led by Oncolytics. The first abstract addresses the preliminary safety and tumor response results from their GOBLET platform study focusing on relapsed anal carcinoma. Under the guidance of Dr. Tom Heineman, Oncolytics' Chief Medical Officer, the studies emphasize the potential of pelareorep to enhance the efficacy of traditional chemotherapy regimens by utilizing the body's immune response. Pelareorep is designed to work in tandem with chemotherapeutic agents and checkpoint inhibitors like atezolizumab, potentially revolutionizing the treatment landscape for patients suffering from pancreatic and anal cancers.

The second abstract presents results from a safety run-in phase involving patients diagnosed with first-line metastatic pancreatic ductal adenocarcinoma (PDAC). Initial findings suggest that pelareorep combined with modified FOLFIRINOX, either alone or alongside atezolizumab, could significantly benefit those battling this aggressive cancer.

The Promise of Immunotherapy

Pelareorep represents a revolutionary class of drugs that leverage the body's innate immune system to combat tumors. By converting